Here are the DEF 14A proxy statements from DiaMedica Therapeutics Inc. (DMAC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow DMAC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMAC filings page.
DiaMedica Therapeutics Inc. is asking shareholders at its May 20, 2026 annual meeting to elect seven directors, ratify Baker Tilly US, LLP as auditor, approve executive pay on an advisory basis, and expand its 2019 Omnibus Incentive Plan.
The plan amendment would add 3,500,000 shares for equity awards, bringing the plan’s total authorization to 10,500,000 shares and extending its term by ten years. As of March 23, 2026, DiaMedica had 53,805,628 common shares outstanding and disclosed a three-year average equity award burn rate of about 5.3%.